-
Artificial intelligence technologies to speed up contouring in radiotherapy treatment planning
Nine artificial intelligence technologies can be used to help plan the treatment of those undergoing external beam radiotherapy for cancers such as lung, prostate or colorectal, NICE has said in draft guidance.
-
NICE recommends extending use of tests for colorectal cancer which could reduce waiting time for colonoscopies
Doctors have been advised to offer people with signs or symptoms of colorectal cancer a home test to reduce the waiting times for a colonoscopy, NICE has said in draft guidance.
-
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use, a NICE committee has said.
-
NICE launches public consultation on updates to health technology evaluations manual
A public consultation on updates to NICE's health technology evaluations manual is now open.
-
New health technologies need new approaches
Dr Sam Roberts has been outlining the changes underway at NICE to meet the challenges of a rapidly evolving health technology sector and patient expectations
-
Decision aid to guide healthcare professional-patient discussions on sleeping pill prescriptions published
Patient decision aid on medicines associated with dependence or withdrawal symptoms published
-
Reducing radiotherapy for some breast cancer patients is likely to have released thousands of appointments for the NHS without compromising safety, NICE finds.
Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term and is now enshrined in NICE guidance.
-
One-stop-shop for AI and digital regulations for health and social care launched
New online advice service launched to help the NHS and wider care system adopt and make use of new digital and artificial intelligence
-
First treatment to target heart condition set to benefit thousands as NICE draft guidance approves NHS use
NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.